All News

It is normal to feel guilt when you survived cancer and friends and family members do not. Here is one writer's way of coping.

Be prepared. After cancer, other medical issues can trigger outsized emotional responses.

The Food and Drug Administration (FDA) recently released a statement providing data from the two phase 3 trials testing Keytruda (pembrolizumab) in patients with multiple myeloma. The trials were placed on clinical holds by the FDA in July, after concerns arose regarding the drug’s safety in this group of patients.

It's been said that reaching the ten-year mark means you are home free. But are you?

With the beginning of the new school year approaching, some parents might be wondering how to manage cancer treatments and the demands of being a parent.

Up-and-coming treatments for patients with triple-negative breast cancer (TNBC) may include immunotherapy combinations, according to Sylvia Adams, M.D.

September is Ovarian Cancer Awareness Month, but many people still aren’t aware of the symptoms and risk factors that can sometimes lead to an ovarian cancer diagnosis. Here are two steps you can take to personalize your approach to ovarian health management by being "ovarian self-aware."

The immunotherapy agent Keytruda (pembrolizumab) had an overall response rate (ORR) of 33 percent in a recent trial including patients with extensive-stage small cell lung cancer (SCLC). Findings of the phase 1b KEYNOTE-028 trial were published in the Journal of Clinical Oncology.

As unpredictable as the weather, the cycle of cancer is often difficult to forecast.

Tips for coping include finding simple ways to pass time and not being in a hurry to go anywhere.

If I’d known I would forget so easily, I would have snapped a photo. I could have easily locked the photo away for safe keeping. When I got the urge to remember, I could have pulled out the photo and looked, but would that have really been a good thing?

A recent study looked at the financial effects that many survivors of childhood cancer face.

In a recent study, researchers were working on identifying different molecular targets to better provide personalized care to patients with ovarian cancer. To do this, they examined more than 4,000 tumor specimins.

A new drug may be on the way to treat patients with advanced melanoma, as the FDA granted LN-144, which is produced by Iovance Biotherapeutics, a fast track designation. The drug uses tumor-infiltrating lymphocyte (TIL) technology to bolster the body’s immune system to attack cancer cells.

A cancer diagnosis robs us of many things. For an avid traveler, its like a bird being trapped in a cage.

A breast cancer and melanoma survivor who also speaks and writes about clutter clearing shares some cancer clutter clearing tips.

Stress reduction is a vital part of breast cancer survivorship. Learn how one survivor incorporated the word

There is a relationship between the genetics of BRCA1 and BRCA2 mutations and the risk of a patient with breast or ovarian cancer being resistant to platinum-based chemotherapy, according to recent research conducted at the Perelman School of Medicine at the University of Pennsylvania. The study’s senior author Katherine Nathanson, M.D., spoke with CURE about these findings.

The FDA has approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML).

A novel agent is attacking a newly found target in patients with acute myeloid leukemia (AML).

Jonathan E. Rosenberg, M.D., discusses the implications of the new treatment guidelines for muscle-invasive bladder cancer.

Coping with losses, one lesson at a time

Studies look at women with peripheral neuropathy after treatment for early-stage breast cancer

Chemo fog, or chemo brain, is a very real phenomena that cancer survivors need to be knowledgeable about. This describes the journey of one survivor.

Although they bring devastation to the whole community hit, catastrophes, such as Tropical Storm Harvey and Hurricane Irma, introduce a new level of difficulty for patients who are being treated for cancer.

RET rearrangements, while they only occur in about 1 percent of patients with non-small cell lung cancer, are nevertheless an important biomarker to identify, since targeted agents have proven to be beneficial in this patient population, and realizing a patient has the mutation can greatly impact their treatment plan, says Christine M. Lovly, M.D., Ph.D.

The newly approved CAR T-cell therapy, Kymriah (tisagenlecleucel), is being put on the market with a price tag of $475,000 for a single infusion, which is within the range that oncologists predicted.

Aromatase inhibitors cause unwanted side effects. More and more women are choosing not to take them, but is this a good idea?

Melanoma survivor offers help based on her own melanoma experience and reading.

Survivor shares that there is no shame to talk to a therapist about life’s difficulties, especially when those difficulties have included coping with a cancer diagnosis and the ongoing fear of recurrence.